Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis
TORONTO – A highly anticipated phase III trial of an anti-tau drug has posted negative topline results, conferring no cognitive or functional benefits when given in conjunction with standard-of-care...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Family Practices | Primary Care